Study of SGR-3515 In Participants With Advanced Solid Tumors.

Conditions

SGR-3515 — DRUG
SGR-3515 will be administered orally with an intermittent schedule.

The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.

Incidence and severity of adverse events (AEs) [ Time Frame: Day 1 to 28 days after the last dose of SGR-3515. ]

Facility	City	State	ZIP	Site coordinators
Yale University, Yale Cancer Center	New Haven	Connecticut	06520	Patricia LoRusso, DO (PRINCIPAL_INVESTIGATOR)
Northwestern University	Chicago	Illinois	60611	Pedro de Viveiros, MD (PRINCIPAL_INVESTIGATOR)
University of Michigan	Ann Arbor	Michigan	48109	Jean Siedel, DO (PRINCIPAL_INVESTIGATOR)
Karmanos Cancer Institute	Detroit	Michigan	48201	Ira Winer, MD (PRINCIPAL_INVESTIGATOR)
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Deborah Doroshow, MD (PRINCIPAL_INVESTIGATOR)
Levine Cancer Institute	Charlotte	North Carolina	28204	Robert W Naumann, MD (PRINCIPAL_INVESTIGATOR)
University of Cincinnati Medical Center	Cincinnati	Ohio	45267	Amanda Jackson, MD (PRINCIPAL_INVESTIGATOR)
Ohio State University	Columbus	Ohio	43210	John Hays, MD (PRINCIPAL_INVESTIGATOR)
Stephenson Cancer Center	Oklahoma City	Oklahoma	73104	Kathleen N Moore, MD (PRINCIPAL_INVESTIGATOR)
Sarah Cannon Research Institute	Nashville	Tennessee	37203	Vivek Subbiah, MD (PRINCIPAL_INVESTIGATOR)
Vanderbilt-Ingram Cancer Center/Henry-Joyce Cancer Clinic	Nashville	Tennessee	37232	Michael K Gibson, MD (PRINCIPAL_INVESTIGATOR)
University of Texas Southwestern	Dallas	Texas	75235	David Miller, MD (PRINCIPAL_INVESTIGATOR)
NEXT Virginia	Fairfax	Virginia	22031	Mohamad A Salkeni, MD (PRINCIPAL_INVESTIGATOR)

By research site